Pseudomyxoma peritonei laboratory findings: Difference between revisions
Mahshid |
|||
| Line 22: | Line 22: | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
[[Category:Up-To-Date]] | |||
[[Category:Oncology]] | |||
[[Category:Medicine]] | |||
[[Category:Gastroenterology]] | |||
[[Category:Surgery]] | |||
Revision as of 15:19, 27 November 2017
|
Pseudomyxoma peritonei Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Pseudomyxoma peritonei laboratory findings On the Web |
|
American Roentgen Ray Society Images of Pseudomyxoma peritonei laboratory findings |
|
Risk calculators and risk factors for Pseudomyxoma peritonei laboratory findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Parminder Dhingra, M.D. [2]
Overview
The laboratory findings associated with pseudomyxoma peritonei are increased levels of tumor markers such as carcinoembryonic antigen (CEA), carbohydrate antigen 19.9 (CA19.9), carbohydrate antigen 125 (CA125).[1]
Laboratory Findings
The laboratory findings associated with pseudomyxoma peritonei are increased levels of tumor markers such as:[1]
These tumor markers are also used as a baseline value for postoperative follow-up. Moreover, they have been reported as predictors of the completeness of cytoreductive surgery, a significant prognostic factor for pseudomyxoma peritonei.